Journal article
Chronic rosiglitazone treatment restores AMPKα2 activity in insulin-resistant rat skeletal muscle
SJ Lessard, ZP Chen, MJ Watt, M Hashem, JJ Reid, MA Febbraio, BE Kemp, JA Hawley
American Journal of Physiology Endocrinology and Metabolism | AMER PHYSIOLOGICAL SOC | Published : 2006
Abstract
Rosiglitazone (RSG) is an insulin-sensitizing thiazolidinedione (TZD) that exerts peroxisome proliferator-activated receptor-γ (PPARγ)-dependent and -independent effects. We tested the hypothesis that part of the insulin-sensitizing effect of RSG is mediated through the action of AMP-activated protein kinase (AMPK). First, we determined the effect of acute (30-60 min) incubation of L6 myotubes with RSG on AMPK regulation and palmitate oxidation. Compared with control (DMSO), 200 μM RSG increased (P < 0.05) AMPKα1 activity and phosphorylation of AMPK (Thr172). In addition, acetyl-CoA carboxylase (Ser218) phosphorylation and palmitate oxidation were increased (P < 0.05) in these cells. To inve..
View full abstract